Yokoyama, Rei
Ago, Yukio http://orcid.org/0000-0001-7562-4000
Igarashi, Hisato
Higuchi, Momoko
Tanuma, Masato
Shimazaki, Yuto
Kawai, Takafumi
Seiriki, Kaoru
Hayashida, Misuzu
Yamaguchi, Shun
Tanaka, Hirokazu
Nakazawa, Takanobu http://orcid.org/0000-0003-4863-1277
Okamura, Yasushi
Hashimoto, Kenji
Kasai, Atsushi http://orcid.org/0000-0002-1612-3078
Hashimoto, Hitoshi
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (JP20H03391, JP22H05080, JP23H02640, JP22J13259, JP22KJ2161, JP20H03392, JP21K19714, JP20H00492, JP21K19335, JP23K00395)
Japan Agency for Medical Research and Development (JP21wm0425017, JP21wm0525005, JP20dm0107122, JP22ama121052, JP22ama121054, JP21dm0207117)
MEXT | Japan Science and Technology Agency (JPMJFR2061)
Takeda Science Foundation
Asahi Glass Foundation
Ministry of Education, Culture, Sports, Science and Technology (JP18H05416)
Article History
Received: 29 August 2023
Revised: 22 December 2023
Accepted: 5 January 2024
First Online: 23 February 2024
Competing interests
: KH is the inventor of filed patent applications on “The use of R-ketamine in the treatment of psychiatric diseases,” “(S)-norketamine and salt thereof as pharmaceutical,” “R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder,” “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases,” and “R-ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder” by the Chiba University. KH has also received speakers’ honoraria, consultant fees, or research support from Abbott, Boehringer Ingelheim, Daiichi-Sankyo, Meiji Seika Pharma, Seikagaku Corporation, Dainippon-Sumitomo, Taisho, Otsuka, Murakami Farm and Perception Neuroscience. All other authors declare they have no competing interests.